A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

• Status: Terminated
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion criteria:

• Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening

• Have a body mass index within range 25 to 40.0kg/m2 inclusive

• Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition)

Exclusion criteria:

• Significant weight loss or gain in the 3 months before screening

• Have used insulin to treat hyperglycemia within 3 months before screening

• Have a history of fluid retention

• Have uncontrolled high blood pressure

• Have liver disease

• Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. - Have or have had certain kinds of cancer